Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Zymeworks Inc.
ZYME
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.9B
$26.01
▲ +1.13%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$11.51 - $29.75
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 99.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary bispecific antibody platform technology with demonstrated efficacy
- Strategic partnerships with major pharmaceutical companies providing validation and resources
- Multi-cancer indication pipeline addressing large addressable markets
- Experienced management team with oncology and biotherapeutic development expertise
Bear Case
2 risks
- Average volatility.
- Significant premium - growth priced in
Growth
Turning profitable
Clinical trial progression and positive efficacy data for zanidatamab and ZW49
Value
Significant premium - growth priced in
Momentum
Stable
-0.3% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ZYME right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
MAY 7, 2026
Reported EPS of -$0.59 vs -$0.10 consensus (-490.0% surprise). Revenue of $2.4M vs $24.4M expected (-90.1%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-490.0%
Next: May 6, 2026
Revenue trend · last 8Q
—
—
+83%
+170%
+153%
+73%
-92%
-91%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$19.2M
$16.0M
$31.0M
$27.1M
$48.7M
$27.6M
$2.5M
$2.4M
Margins · last 8Q
Gross
—
Operating
—
Profit
-1834.0%
Wall Street consensus
7 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$46.00
▲ +76.9% vs $26.01
Latest: Wells Fargo · Jun 30, 2026
1 analyst covering